DE602007013648D1 - Tartratsalz aus Isofagomin und Verwendungsverfahren dafür - Google Patents

Tartratsalz aus Isofagomin und Verwendungsverfahren dafür

Info

Publication number
DE602007013648D1
DE602007013648D1 DE602007013648T DE602007013648T DE602007013648D1 DE 602007013648 D1 DE602007013648 D1 DE 602007013648D1 DE 602007013648 T DE602007013648 T DE 602007013648T DE 602007013648 T DE602007013648 T DE 602007013648T DE 602007013648 D1 DE602007013648 D1 DE 602007013648D1
Authority
DE
Germany
Prior art keywords
isofagomine
salt
tartrate salt
gaucher disease
isofagomine tartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013648T
Other languages
English (en)
Inventor
Benjamin Mugrage
David Palling
Kamlesh A Sheth
Philip J Rybczynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of DE602007013648D1 publication Critical patent/DE602007013648D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
DE602007013648T 2006-05-24 2007-05-23 Tartratsalz aus Isofagomin und Verwendungsverfahren dafür Active DE602007013648D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US89071907P 2007-02-20 2007-02-20

Publications (1)

Publication Number Publication Date
DE602007013648D1 true DE602007013648D1 (de) 2011-05-19

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013648T Active DE602007013648D1 (de) 2006-05-24 2007-05-23 Tartratsalz aus Isofagomin und Verwendungsverfahren dafür

Country Status (14)

Country Link
US (2) US7501439B2 (de)
EP (1) EP1860101B1 (de)
JP (1) JP5292605B2 (de)
AT (1) ATE504570T1 (de)
AU (1) AU2007202359B2 (de)
BR (1) BRPI0706114A2 (de)
CA (1) CA2590122C (de)
DE (1) DE602007013648D1 (de)
DK (1) DK1860101T3 (de)
IL (1) IL183415A (de)
MX (1) MX2007006175A (de)
PL (1) PL1860101T3 (de)
PT (1) PT1860101E (de)
WO (1) WO2007140212A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) * 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
KR101597499B1 (ko) * 2007-05-22 2016-02-24 아미쿠스 세라퓨틱스, 인코포레이티드 이소파고민과 이의 유도체를 제조하는 새로운 방법
EP2946785B1 (de) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Verfahren zur vorhersage der reaktion auf die behandlung von krankheiten mit pharmakologischen chaperonen
EP2361089A4 (de) * 2008-11-14 2012-08-22 Parkinson S Inst Behandlung einer veränderten synuclein-funktion
CN102686237B (zh) 2009-07-28 2018-10-19 夏尔人类遗传性治疗公司 用于治疗戈谢病的组合物
PT2995306T (pt) * 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
ES2814178T3 (es) 2009-10-19 2021-03-26 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
ES2724531T3 (es) 2011-05-12 2019-09-11 Proteostasis Therapeutics Inc Reguladores de proteostasis
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
AU2013240486B2 (en) 2012-03-27 2017-10-26 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
JP2015512913A (ja) * 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
EP3318277A1 (de) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitoren der glucosylceramidsynthase zur behandlung von motoneuronerkrankungen
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
BR112020007820A2 (pt) * 2017-10-26 2020-10-20 Shire Human Genetic Therapies, Inc. formulações compreendendo glucocerebrosidase e isofagomina
CN112585132A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
EP3814336A1 (de) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Verbindungen zur erhöhung der proteasomaktivität
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP2022530017A (ja) * 2019-04-25 2022-06-27 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Also Published As

Publication number Publication date
BRPI0706114A2 (pt) 2008-11-18
US7501439B2 (en) 2009-03-10
AU2007202359B2 (en) 2012-02-16
IL183415A0 (en) 2007-09-20
US7863453B2 (en) 2011-01-04
PL1860101T3 (pl) 2011-10-31
CA2590122A1 (en) 2007-11-24
PT1860101E (pt) 2011-07-12
EP1860101A1 (de) 2007-11-28
DK1860101T3 (da) 2011-07-25
JP2007314540A (ja) 2007-12-06
MX2007006175A (es) 2009-02-16
US20090176830A1 (en) 2009-07-09
AU2007202359A1 (en) 2007-12-13
WO2007140212A2 (en) 2007-12-06
EP1860101B1 (de) 2011-04-06
US20070281975A1 (en) 2007-12-06
WO2007140212A3 (en) 2008-12-24
IL183415A (en) 2012-03-29
JP5292605B2 (ja) 2013-09-18
CA2590122C (en) 2015-03-31
ATE504570T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
DE602007013648D1 (de) Tartratsalz aus Isofagomin und Verwendungsverfahren dafür
ATE530519T1 (de) Cyclobutylaminderivate
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
RS52754B (en) MALATE IS N- (4- {[6,7-BIS (METHYLOXY) HINOLIN-4-IL] OXY} PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMID, AND ITS CRYSTAL FORMS FOR CARCINOMA TREATMENT
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE441632T1 (de) Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
DE602005021196D1 (de) Halbleiterbauelement und eine Methode zur dessen Herstellung
ATE445587T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
DE602006015984D1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
DE602006013271D1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen
NO20075111L (no) Farmasoytisk sammensetning
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
MY146802A (en) Novel drugs for treating respiratory diseases
EA201001773A1 (ru) Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
ATE440836T1 (de) Verbindungen
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
HUP0500975A2 (en) Process for producing of extract of sour cherry seed, use of extract for producing of medicament and medicaments consist extract